Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.75 |
| ▸ | RAB9A | P51151 | 5/20 | 0.75 |
| ▸ | MAOB | P27338 | 5/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | NPC1 | O15118 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | GAPDH | P04406 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.71 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | MIF | P14174 | 3/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177366 | 0.86 | RAB9A (1.00) | KDM4ERAB9AMAOBALDH1A1NPC1 | |
| SCHEMBL30356319 | 0.86 | RAB9A (1.00) | KDM4ERAB9AMAOBALDH1A1NPC1 | |
| SCHEMBL12813480 | 0.85 | MIF (0.63) | KDM4ERAB9AMAOBALDH1A1NPC1 | |
| SCHEMBL28045576 | 0.85 | MIF (0.77) | KDM4ERAB9AMAOBALDH1A1NPC1 | |
| SCHEMBL4054863 | 0.84 | RAB9A (0.73) | KDM4ERAB9AMAOBALDH1A1NPC1 | |
| SCHEMBL4064740 | 0.83 | ALDH1A1 (1.00) | KDM4ERAB9AMAOBALDH1A1NPC1 | |
| SCHEMBL14389070 | 0.83 | MAOB (0.75) | KDM4ERAB9AMAOBALDH1A1NPC1 | |
| SCHEMBL30096432 | 0.83 | NCOA1 (1.00) | KDM4ERAB9AMAOBALDH1A1NPC1 | |
| SCHEMBL2929526 | 0.83 | ALDH1A1 (0.75) | KDM4ERAB9AMAOBALDH1A1NPC1 | |
| SCHEMBL8788473 | 0.83 | RAB9A (0.75) | KDM4ERAB9AMAOBALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| US-RE46558-E1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-RE46558-E1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9381187-B2 | Radiation countermeasure agents | PALOMA PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381187-B2 | Radiation countermeasure agents | PALOMA PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015154047-A1 | NOVEL METHODS | RESTORGENEX CORPORATION (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS INC (US) | 2014-04-17 | — | — | US | disclosed |
| US-20110021618-A1 | METHODS OF TREATING FIBROTIC DISORDERS | PALOMA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2007101247-A2 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| US-6555523-B1 | Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus | CASCADE ESTATES LTD. (MU) | 2003-04-29 | — | — | US | disclosed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, TYR | KDM4E 1817/4885RAB9A 3007/4885MAOB 946/4885 |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, FLT1 | KDM4E 3557/4885RAB9A 3736/4885MAOB 1462/4885 |
| US-20110021618-A1 | METHODS OF TREATING FIBROTIC DISORDERS | COL2A1, MMP1, COL1A1 | KDM4E 2823/4885RAB9A 2980/4885MAOB 1928/4885 |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, HDGF | KDM4E 3839/4885RAB9A 3722/4885MAOB 1365/4885 |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | MKI67, VEGFA, TYR | KDM4E 1817/4885RAB9A 3007/4885MAOB 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.